Science
Unlocking new therapies for poor prognosis cancers, through an in-house created platform of original small molecules.
Our product development & research
Karion Therapeutics developed a portfolio of exciting bioactive molecules using new synthetic manufacturing methods.
KT408 is a patented small molecule and our first oncology drug candidate. KT408 presents robust preclinical data, being effective and potent against different poor prognosis cancers, outperforming biological profile over currently used clinical drugs.
KT408 is a promising and innovative treatment, increasing survival and quality of life of cancer patients.
THERAPEUTIC FOCUS
KT408 targets core tumorigenic mechanisms, with a mode of action that will revolutionize clinical paradigms beyond traditional small molecule-based targeted therapies.
At Karion Therapeutics we are focused on finding an efficient and safe treatment for aggressive cancers that represent urgent unmet medical needs.
Our preclinical studies focus on triple negative breast cancer (TNBC) and Renal cell Carcinoma (RCC). New therapeutic options are urgently needed to increase patient survival and their quality of life.
TNBC PATIENTS URGENTLY NEED NEW TREATMENTS
TNBC accounts for 15-20% of breast cancers.
Chemotherapy, surgery and radiation are the main treatment options.
Poor response to therapy, associated with high drug resistance (50%), high patient relapse rates (50%, early stages I-III) and severe side effects, are major problems.
The most advanced treatments such as Parp inhibitors and immunotherapy are insufficient, since patients display only partial response (10-18% and 10-20%, respectively), leaving the remaining patients with no viable option.
High 5-year mortality rate: 35% for stage III patients, raising up to 90% for stage IV.
RCC PATIENTS URGENTLY NEED NEW TREATMENTS
RCC accounts for 90 to 95% of all kidney malignant neoplasms and is frequently detected at an advanced stage.
Although significant advances have been made for targeted drug approaches, such as tyrosine kinase inhibitors and immunotherapy, patients exhibit low response rates to these therapeutic options, associated with high relapse rates (30%) and significant drug resistance (6-10 months after treatment initiation).
High 5-year mortality rate: 30% for stage III, raising up to 90% for stage IV tumors.
KT408 represents a new beyond for cancer patients, targeting cancer at the core!
PIPELINE
Developing next level therapies for cancer
Karion Therapeutics develops innovative drug candidates to improve patients' outcomes, targeting aggressive cancers with high unmet medical need.
CONTACT US
KARION THERAPEUTICS, LDA.
SCHOOL OF MEDICINE, UNIVERSITY OF MINHO, CAMPUS DE GUALTAR,
4710-057 BRAGA, PORTUGAL
Developed by Studio Ayer
KARION THERAPEUTICS 2023 © ALL RIGHTS RESERVED